Skip to main content
Clinical Trials/NCT02044562
NCT02044562UnknownNot Applicable

Study of Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients Receiving Concurrent Chemo-radiotherapy

Capital Medical University1 site in 1 country20 target enrollmentStarted: September 1, 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
20
Locations
1
Primary Endpoint
plasma nitrate level

Study Overview

Brief Summary

The purpose of this study is to evaluate whether dietary nitrate supplementation could improve the plasma nitrate levels for nasopharyngeal carcinoma patients receiving concurrent chemo-radiation therapy.

Detailed Description

Twenty patients diagnosed as nasopharyngeal carcinoma will be recruited. A 70 ml beetroot juice containing 0.45g nitrate or placebo will be provided to the patients for 7 days at the end of the radiotherapy . The plasma nitrate levels will be determined before radiotherapy, before intervention and after intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
20 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with newly diagnosed stages III-IVb (UICC 2002) nasopharyngeal carcinomas, will be recruited.

Exclusion Criteria

  • Patients with local invasion or metastatic foci in salivary glands, detected by MRI and PET-CT prior to treatment, were excluded, as were patients suffering from diseases, such as Sjogren's syndrome, or with a history of surgery to major salivary glands, or prior head and neck radiotherapy.

Outcomes

Primary Outcomes

plasma nitrate level

Time Frame: one day after nitrate supplementation

The plasma nitrate level will be determined one day after nitrate supplementation.

Secondary Outcomes

  • quality of life(one day after nitrate supplementation)

Investigators

Sponsor
Capital Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Songlin Wang

Professor and Vice President

Capital Medical University

Study Sites (1)

Loading locations...

Similar Trials